Highlights from the Week of 15th June 2026 - 22nd June 2026 ( FDA, Approval ) Merck's CAPVAXIVE gets FDA approval for an expanded indication that includes those aged 12-17 years with an increased pneumococcal disease risk ( FDA, Approval ) AbbVie's Allergan Aesthetics receives FDA approval for SKINVIVE by JUVÉDERM to reduce neck lines in adults over the age of 21 ( FDA, Approval ) FDA approves GSK and Spero Therapeutics' UTEBZI for the treatment of cUTIs, including pyelonephritis, in adults with limited or no alternative oral options ( EU, Approval ) EC gives centralized marketing authorization to CinnaGen's ZANDORIAH, a biosimilar for the treatment of osteoporosis in adults Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 15th June – 22nd June in the world of pharma and healthcare!

Uncategorized /

Highlights from the Week of 15th June – 22nd June in the world of pharma and healthcare! Read More »